I think most of us want the company sold and sold sooner rather than later. The problem is the company is being run by guys who think they know better than all of us and think their plan is going just great. I do not think they have any intention of ever selling. They do not care they are getting rich off of AMRN.
I hear you, and because I believe that's how the story will end I'm adding when I can to lower my average (currently at $2.89). Right now $7 is my exit target but $5 wouldn't be a disaster if that's the sale price.
Optimally we get some movement on the Denner front and the premiums for selling Jan 2024 calls increase a bit. Would love to sell 600 at $7 strike and buy more shares with the proceeds.
And the analysts, in print or on television and other media, have been advising to buy biotechnology companies, inasmuch as those companies are turning a corner and will advance the rest of 2022 into 2023. Really?
Indices such as GNOM, LABU, XBI, IBB remain close to bottoms for the year. Managing a portfolio of biotechs remains unpredictable day to day, dependent on trial results, income, milestones and royalties like always. More later on this topic.
Market Data 
Markets 
